Launch week offerEnds in00h00m00s

annual Promonthly Pro

Rami Komrokji

Vice chair

H Lee Moffitt Cancer Center and Research Institute

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Collaborators (14)

Somedeb Ball

Vanderbilt University Medical Center

UNITED STATES

View details

María Díez Campelo

Universidad de Salamanca

SPAIN

View details

ROSA MARIA AYALA DIAZ

Full Professor

Universidad Complutense de Madrid

SPAIN

View details

Geoffrey Uy

Professor of Medicine

Washington University School of Medicine

UNITED STATES

View details

Michael Savona

Beverly and George Rawlings Director of Hematology Research and Professor of Medicine and Cancer Biology

Vanderbilt University

UNITED STATES

View details

Gabriela Hobbs

Massachusetts General Hospital

UNITED STATES

View details

Aaron Gerds

Assitant Professor

Cleveland Clinic

UNITED STATES

View details

Yazan F. Madanat

University of Texas Southwestern Medical Center

UNITED STATES

View details

Amer M. Zeidan

Yale University School of Medicine

UNITED STATES

View details

VALERIA SANTINI

ASSOCIATE PROFESSOR

University of Florence

ITALY

View details

David Swoboda

UNITED STATES

View details

lionel adès

Professor

FRANCE

View details

Tim Somervaille

Cancer Research UK Manchester Institute

UNITED KINGDOM

View details

Mikko Myllymäki

FIMM-EMBL Group Leader

University of Helsinki

FINLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Rami Komrokji

Research Interests

Make your next move.

Explore related searches

Articles (20)

Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial

Clinical features and outcomes of MPN with concurrent MPL and JAK2/CALR Mutations

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study

Oral Azacitidine Maintenance After CPX‐351 in Transplant‐Ineligible Patients With Therapy‐Related or Myelodysplasia‐Related Acute Myeloid Leukemia

Hematologic responses achieved with luspatercept in higher-risk myelodysplastic syndromes

CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?

Exposure to Agent Orange and association with myelodysplastic syndromes

Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response

Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression

Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with &lt;i&gt;TP53&lt;/i&gt; mutant MDS/AML.

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

Transfusion Independence Corresponds With Survival in Patients With Lower-Risk Myelodysplastic Syndrome: Real-World Evidence From United States Insurance Claims

Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival

How I treat higher-risk MDS

Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion

Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis

Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence.

Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm

Collaborators (14)

Somedeb Ball

María Díez Campelo

ROSA MARIA AYALA DIAZ

Geoffrey Uy

Michael Savona

Gabriela Hobbs

Aaron Gerds

Yazan F. Madanat

Amer M. Zeidan

VALERIA SANTINI

David Swoboda

lionel adès

Tim Somervaille

Mikko Myllymäki

Make your next move.

Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AML.